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INTRODUCTION
Allogeneic stem cell transplantation (ASCT) has been
widely used in the treatment of hematologic malignancies.
High-dose myeloablative chemotherapy followed by allo-
geneic bone marrow or peripheral blood stem cell trans-
plantation has successfully treated many otherwise incurable
patients [1,2]. However, regimen-related toxicities (RRTs)
can be severe and sometimes fatal [3-6]. ASCT in patients
Phase II Study of a Moderate-Intensity Preparative
Regimen with Allogeneic Peripheral Blood Stem Cell
Transplantation for Hematologic Diseases: The Texas
Transplant Consortium Experience
P. J. Shaughnessy,6 D. Ornstein,1 D. Ririe,1 N. Callander,2 J. E. Anderson,2 M. S. Pollack,2 C. O. Freytes,3
J. Cruz,4 T. Rodriquez,5 C. Bachier,6 C. F. LeMaistre6
1Wilford Hall Medical Center, San Antonio; 2University of Texas Health Science Center, San Antonio; 3Audie L Murphy
Veterans Administration, San Antonio; 4Texas Tech University, Lubbock, Texas; 5Rush Presbyterian St Lukes Medical
Center, Chicago, Illinois; 6Texas Transplant Institute, San Antonio, Texas
Correspondence and reprint requests: Paul J. Shaughnessy, MD, Texas Transplant Institute, 8201 Ewing Halsell Suite 280,
San Antonio, TX 78229 (e-mail: shaughnessy@TexasTransplant.org).
Received December 18, 2001; accepted May 16, 2002
ABSTRACT
Conventional preparative regimens for allogeneic stem cell transplantation are associated with excessive regimen-
related toxicity (RRT) in some patients because of underlying comorbidities, advanced age, or prior treatment. We
studied a preparative regimen designed to reduce RRT, yet allow for adequate engraftment and development of a graft-
versus-malignancy effect. Thirty patients (median age, 57 years) were entered on study. Twenty-nine patients received
stem cells from HLA-identical siblings and 1 from a sibling mismatched for 1 antigen at the A locus. Sixteen patients
had received previous stem cell transplants (6 allogeneic and 10 autologous). The preparative regimen consisted of flu-
darabine 30 mg/m2 per day IV on day –10 to day –5, busulfan 1 mg/kg per dose PO (n = 6) or 0.8 mg/kg per dose IV
(n = 24) for 8 doses every 6 hours on day –6 to day –5, and horse-derived antithymocyte globulin 5 mg/kg per day IV
(n = 12) or 15 mg/kg per day IV (n = 18) on day –4 to day –1. GVHD prophylaxis consisted of cyclosporine (CYA)
3 mg/kg BID PO starting on day –3 (n = 13) or CYA and methotrexate 15 mg/m2 IV on day +1 and 10 mg/m2 IV on
day +3 and day +6 (n = 17). The median number of CD34+ cells transplanted was 3.19 × 106/kg. All patients demon-
strated recovery of hematopoietic function. Twenty-six (89%) of 29 evaluable patients achieved greater than 90% donor
cell chimerism before day 100. Three patients never achieved greater than 90% donor chimerism, and another
3 patients subsequently lost donor chimerism. All 6 of these patients had autologous reconstitution with progressive
disease. RRT was minimal; 7 patients had greater than grade II nonhematologic toxicity and there were no toxic deaths
attributable to the conditioning regimen. Transplantation-related mortality was 7% (95% confidence interval [CI],
6%-8%) at 3 months and 28% (95% CI, 23%-34%) at 12 months after transplantation. Non–relapse-related mortality
was most often due to infection. Grade II or greater GVHD developed in 56% of evaluable patients, and all patients
with disease response developed GVHD. Actuarial estimates of overall and disease-free survival at 12 months were 52%
(95% CI, 43%-63%) and 30% (95% CI, 24%-37%), respectively. Although this preparative regimen allowed adequate
engraftment with minimal RRT, GVHD and infectious complications caused significant morbidity and mortality. Further
study to define appropriate patient populations for this regimen, while limiting GVHD and infection risks, is needed.
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older than 45 years is associated with a higher incidence of
graft-versus-host disease (GVHD), end organ damage, and
decreased survival compared to younger patients [5-6].
Patients who receive an ASCT after previous high-dose
chemotherapy may also have excessive morbidity and mor-
tality [7,8]. RRT has generally limited the use of ASCT to
younger patients with good performance status. A signifi-
cant number of patients have diseases that may be amenable
to treatment with ASCT but are at high risk for severe RRT
because of underlying comorbidities.
Conditioning regimens for ASCT were initially designed
to destroy the underlying malignancy and immunosuppress
the host to allow donor engraftment and prevent graft rejec-
tion. Data from murine stem cell transplantation models
suggested that some hematologic malignancies were not
curable even with the most intensive and otherwise lethal
preparative regimens [1]. More recently, it has been demon-
strated that the antitumor effect of the transplanted cells
may be a major factor in the success of ASCT in eradicating
malignancy. Weiden et al. described the GVH and graft-
versus-leukemia effect in 1979, demonstrating that the allo-
graft might have a role in eradicating the malignant clone
beyond just rescuing the hematopoietic function of the bone
marrow [9]. The immunologic power of ASCT is further
supported by the results of donor lymphocyte infusion
(DLI) data in patients with relapsed leukemias after ASCT
[10-18]. DLI can result in complete and sustained remis-
sions of disease in some patients without the use of cytotoxic
drugs. This graft-versus-leukemia effect, which may more
broadly be referred to as a graft-versus-malignancy (GVM)
effect, may also be active, although to a lesser extent, in mul-
tiple myeloma [19-22], non-Hodgkin’s lymphoma [23], and
renal cell carcinoma [24]. The curative effect of ASCT may,
therefore, be a result of the GVM effect rather than the
cytotoxic properties of the conditioning regimen. Decreas-
ing the cytotoxicity and maximizing the immunosuppressive
effects of the preparative regimen may allow for adequate
engraftment and development of the GVM effect, while
ameliorating RRT.
Studies of reduced-dose conditioning regimens and
ASCT have been reported by several centers [25-41]. One
of the first reports by Slavin et al. described a reduced-
intensity preparative regimen for hematologic diseases that
demonstrated acceptable engraftment rates, disease control,
and survival, with decreased RRT [25]. Based on this experi-
ence we designed a similar phase II multi-institutional pro-
tocol to evaluate the feasibility of using a similar preparative
regimen and ASCT in patients at high risk for RRT.
MATERIALS AND METHODS
Patients and Donors
Thirty patients were entered on study between June
1998 and May 2001. The protocol was conducted through
the Texas Transplant Consortium, and all patients were
recruited through the following member institutions in San
Antonio, Texas: Wilford Hall Medical Center, University of
Texas Health Science Center at San Antonio, Audie L. Mur-
phy Veterans Administration Hospital, and the Texas Trans-
plant Institute. Institutional review boards of participating
centers approved protocols and informed consent docu-
ments. All study patients were judged not to be candidates
for standard myeloablative preparative regimens because of
comorbid illnesses, age greater than 55 years, prior high-
dose chemotherapy, or combinations of the above. All
patients gave informed consent.
All donors were HLA-identical siblings except one
donor who had a mismatch with the recipient for 1 antigen
at the A locus. Donor peripheral blood stem cells were col-
lected by apheresis after 4 to 5 days of treatment with gran-
ulocyte colony-stimulating factor (GCSF) (5 to 10 µg/kg
per day) with a goal of collecting 2 × 106 CD34+ cells per kg
recipient weight.
Preparative Regimen
The preparative regimen consisted of fludarabine
30 mg/m2 per day IV on day –10 to day –5, busulfan
1 mg/kg per dose orally (PO) (n = 6) or 0.8 mg/kg per dose
intravenously (IV) (Busulfex, Orphan Biomedical, Min-
netonka, MN) (n = 24) for 8 doses every 6 hours on day –6
to day –5, and horse-derived antithymocyte globulin (ATG)
(ATGAM; UpJohn, Kalamazoo, MI) 5 mg/kg per day IV
(n = 12) or 15 mg/kg per day IV (n = 18) on day –4 to
day –1. GVHD prophylaxis consisted of cyclosporine (CYA)
3 mg/kg twice a day (BID) PO starting on day –3 (n = 13),
or CYA and methotrexate (MTX) 15 mg/m2 IV on day +1,
and 10 mg/m2 IV on day +3 and day +6 (n = 17). Intra-
venous busulfan was substituted for oral busulfan when it
became available at study sites. The change in dose of
equine ATG and the addition of MTX for GVHD prophy-
laxis as described above were made by protocol amendment
because of grade III and IV acute GVHD observed in
patients who received CYA alone.
Supportive Care
The conditioning regimen initially was designed to be
administered in the outpatient clinic. Patients were hospital-
ized for administration of frequent IV medicines, neu-
tropenic fever, inability to maintain adequate oral intake, or
at the discretion of the attending physician. All patients
seropositive for herpes simplex virus received acyclovir
400 mg PO 3 times a day (TID) beginning day –10 through
engraftment and then 200 mg PO TID until day 60. Flu-
conazole 400 mg PO once daily was begun on day –10 and
given through day 60. A ﬂuoroquinolone was added when
the absolute neutrophil count (ANC) fell below 1.0 × 109/L
and was continued until ﬁrst neutropenic fever, or the ANC
recovered to greater than 0.5 × 109/L for 2 consecutive days
with no other documented infection. Cytomegalovirus
(CMV) reactivation was treated with ganciclovir 5 mg/kg IV
BID for 7 days, then every day afterward until resolution of
viremia. Trimethoprim-sulfamethoxazole was administered
daily on day –10 to day –1 and then 2 or 3 times weekly after
engraftment, or pentamidine by inhalation every 4 weeks was
given for prophylaxis against Pneumocystis carinii infection.
Phenytoin, 300 mg PO TID given on days –11 through –8
and then 300 mg PO once daily on day –7, was administered
for antiseizure prophylaxis and then discontinued. GCSF
5 µg/kg subcutaneously daily (rounded to either 300 µg or
480 µg) starting on day +7 was given to 23 patients and con-
tinued until the ANC exceeded 1.5 × 109/L for 2 consecutive
days or the ANC was greater than 3.0 × 109/L for 1 day.
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Engraftment, Chimerism Analysis, and Donor
Lymphocyte Infusion
Hematopoietic cell engraftment was deﬁned as the ﬁrst
of 3 consecutive days on which an ANC greater than 0.5 ×
109/L was achieved. All chimerism analysis was done on
total peripheral blood nucleated cells. Red blood cells were
lysed prior to DNA extraction. At Wilford Hall Medical
Center, Audie L. Murphy Veterans Administration Hospital,
and University of Texas Health Science Center in San Anto-
nio, chimerism analysis was done by a quantitative assay that
uses the polymerase chain reaction (PCR) to amplify poly-
morphic short tandem repeat loci. Primer pairs complemen-
tary to conserved sequences on either side of the variable
length regions were used to amplify fragments that were of
different lengths for different individuals. Primers were syn-
thesized with a Cy5.5 label attached to the 5′ direction (for-
ward) primer. The fragment sizes were measured by their
migration distance in a sequencing gel and were compared
to known alleles and to labeled molecular weight markers
using Visible Genetics software (Toronto, Ontario, Canada).
Genotypes of the donor and recipient were assigned for
each genetic locus by comparing PCR product sizes with
commercially prepared size standards. In posttransplanta-
tion samples, the relative quantities of donor and recipient
DNA were calculated from measurements of the areas under
informative peaks. Whenever possible, posttransplantation
recipient samples were tested in parallel with a donor sam-
ple, a pretransplantation recipient sample, and known mix-
tures of the two. The mixtures were selected to approximate
the expected results and to determine the level of sensitivity
for detection for each test system. When recipient pretrans-
plantation samples were not available, buccal mucosal cells
were collected with the caveat that they frequently contain
an admixture of donor cells in engrafted patients. Chimerism
analysis at the Texas Transplant Institute was performed by
Lab Corp (Laboratory Corporation of America, Burlington
NC) using similar methods. Variable and short tandem
repeat DNA regions were amplified and allele sizes were
analyzed after electrophoresis in vertical gels and detected
by silver staining. Allele sizes were compared with size stan-
dard ladders and previously tested standard samples.
Chimerism analysis of peripheral blood was done on
days 28, 56, and 80. CYA was stopped immediately if there
were signs of disease progression or there was less than 90%
donor chimerism. CYA was tapered after the day 28 analysis
if there was no evidence of acute GVHD. The dose was
decreased by 25% in weekly intervals and discontinued by
day 56. CYA could be reinstituted or the dose increased if
GVHD occurred. DLI was administered if there was less
than 90% donor chimerism and CYA had been discontin-
ued, or if there was evidence of disease progression and no
active GVHD. Donor lymphocytes were collected without
cytokine mobilization by leukopheresis at the time DLI was
deemed necessary. DLI was administered in a single infusion
or in stepwise increments at the discretion of the attending
physician. Cell doses ranged from 1 × 107 to 5 × 108 CD3+
cells per kg recipient body weight.
Data Analysis
Complete remission was determined by standard disease-
speciﬁc criteria as deﬁned by the International Bone Mar-
row Transplant Registry (IBMTR). Acute and chronic
GVHD were scored according to published guidelines
[42,43]. Toxicity was graded by World Health Organization
classification of Common Toxicity Criteria. Venoocclusive
disease (VOD) of the liver was diagnosed by standard crite-
ria [44]. Pearson’s chi-square test was used to compare
GVHD prophylaxis groups. Unadjusted probabilities of
transplantation-related mortality (TRM), overall survival
(OS), and disease free survival (DFS), deﬁned as the number
of months from the day of stem cell transplantation, were
estimated using the Kaplan-Meier method [45].
RESULTS
Patient Characteristics
Thirty patients underwent ASCT on this protocol. There
were 23 men and 7 women. The median age was 57 years
(range, 27-69 years). All patients had relapsed or persistent
disease at the time of transplantation and had failed to
respond to at least one prior therapy. The median number of
prior therapies was 3. Three chronic-phase chronic myeloge-
nous leukemia (CML) patients failed interferon as their only
prior treatment. Sixteen patients had undergone previous
stem cell transplantation (6 allogeneic and 10 autologous).
Patient and donor characteristics, as well as variations in the
preparative regimen, are summarized in Table 1.
Toxicities
Seven (23%) of the patients had greater than grade II
nonhematologic RRT. Three patients had grade III and
1 patient had grade IV nausea and vomiting. Two patients
had grade III and 2 patients had grade IV mucositis. One
patient had grade III diarrhea. Grade IV pulmonary toxicity
was seen in 2 patients, both of whom had received prior
high-dose therapy. Patient 6 received interleukin (IL)-2 off
protocol after engraftment and developed capillary leak,
adult respiratory distress syndrome, and pulmonary effu-
sions requiring mechanical ventilation. Patient 9 developed
respiratory failure requiring mechanical ventilation 3 days
posttransplantation. An open lung biopsy on day 28 revealed
bronchiolitis obliterans and organizing pneumonia (BOOP).
Six of the 7 patients who developed greater than grade II
nonhematologic toxicity had had prior high-dose chemo-
therapy. Serum sickness was diagnosed in 11 (37%) of the
patients. The diagnosis of serum sickness was made clinically
based on a temporal relationship between ATG administra-
tion and presence of 2 or more of the following symptoms:
arthralgia, myalgia, erythematous rash, and fever. VOD was
not diagnosed in any patient.
Engraftment
All patients had hematologic recovery with and ANC
greater than 0.5 × 109/L at a median of day 13 (range, 9-25 days).
The protocol was amended to allow the use of GCSF as
described above because of prolonged neutrophil nadirs in
the first 6 patients treated. Three patients who failed to
achieve platelet engraftment had progressive disease with
bone marrow involvement. Six patients did not have platelet
nadirs below 20 × 109/L. Packed red blood cells and platelet
support were not required in 7 and 8 patients, respectively,
during the first 30 days after transplantation. Twenty-nine
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patients were evaluable for chimerism analysis (Table 2);
chimerism studies were not performed in 1 patient. Twenty-
six (89%) of the patients had greater than 90% donor
chimerism before day 100. Three patients never achieved
greater than 90% donor chimerism, and another 3 patients
lost donor chimerism before day 100. All 6 patients had
disease involving the bone marrow at the time of their
transplantation (3 CML, 2 myeloﬁbrosis, 1 chronic myelo-
monocytic leukemia) and subsequently had autologous
reconstitution and disease progression. Five of the 6 patients
received DLI and 1 patient refused further therapy. All 5 of
these patients failed to respond to the DLI and continued to
manifest progressive disease and decreased donor chimerism.
Ten patients relapsed or had progressive disease despite
greater than 90% donor chimerism. Of these 10 patients,
4 refused or were too ill to receive further therapy; 3 had
active GVHD at the time of disease progression and, there-
fore, did not receive DLI; 2 received DLI but failed to
respond; and 1 received DLI and appeared to be responding,
but died of a cerebral hemorrhage.
Graft-versus-Host Disease
Grades II to IV acute GVHD occurred in 8 (62%) of
13 patients who received CYA alone and 9 (52%) of 17 patients
who received CYA/MTX (P = not significant) (Table 2).
Twenty patients were evaluable for chronic GVHD, which
occurred in 4 (50%) of 8 patients in the CYA-alone group
and 5 (42%) of 12 patients in the CYA/MTX group (P =
NS) (Table 2). In the CYA-alone GVHD prophylaxis group,
2 patients had grade IV acute GVHD. In the CYA/MTX
group, 1 patient had grade III and no patients had grade IV
acute GVHD . Five patients (17%) died with complications
related to GVHD. One patient died of steroid refractory
acute GVHD, and 4 others died of infection while their
GVHD was quiescent on systemic corticosteroids.
Infections
Febrile neutropenia occurred in 19 (63%) of 30 patients
in the immediate transplantation period (before day 30);
however, 4 patients had fever only during the administration
of the ATG. Five patients died of infectious causes between
Table 1. Patient, Donor, and Transplantation Characteristics*
Patient Patient Prior High-Risk Donor Prep Regimen GVHD
ID Disease Age/Sex Therapies Characteristics Age/Sex Variations† Prophylaxis
1 CML CP 51/F 1 Diabetic, obese 46/M IV Bu, 5 mg/kg ATG CYA 
2 CML CP 47/F 1 Coag, PXE 44/F PO Bu, 5 mg/kg ATG CYA
3 MDS/CMML 61/M 4 Age 51/M PO Bu, 5 mg/kg ATG CYA
4 NHL MC 69/M 4 Age 81/F IV Bu, 5 mg/kg ATG CYA
5 CML CP 65/M 1 Age, nephrectomy 68/M IV Bu, 5 mg/kg ATG CYA
6 AML-M7 27/M 2 Previous allo 32/F IV Bu, 5 mg/kg ATG CYA
7 MM 48/M 2 Previous auto 51/M IV Bu, 5 mg/kg ATG CYA/MTX
8 CLL 58/M 4 Age 59/M PO Bu, 5 mg/kg ATG CYA
9 CML BP 59/F 2 Age, previous allo, MI 56/M IV Bu, 15 mg/kg ATG CYA
10 MDS/RA 57/M 4 Age 62/M IV Bu, 15 mg/kg ATG CYA
11 MM 66/M 3 Age, previous auto 62/F IV Bu, 15 mg/kg ATG CYA
12 NHL DLC 38/M 4 Previous auto 40/F IV Bu, 15 mg/kg ATG CYA
13 MM 59/M 3 Age, Previous auto 55/M IV Bu, 15 mg/kg ATG CYA/MTX
14 NHL T-cell 58/M 3 Age 55/M PO Bu, 5 mg/kg ATG CYA
15 HD 46/M 3 Prior therapies 52/F PO Bu, 5 mg/kg ATG, CYA/MTX
16 CML CP 47/M 2 Previous allo 42/F IV Bu, 15 mg/kg ATG CYA/MTX
17 MF 57/M 2 Age, previous allo 53/F IV Bu, 5 mg/kg ATG CYA/MTX
18 MF 65/M 2 Age, CAD, CVA 76/M IV Bu, 15 mg/kg ATG CYA/MTX
19 MM/plasmacytoma 43/F 4 Previous auto 45/M IV Bu, 15 mg/kg ATG CYA/MTX
20 NHL MC 59/M 4 Age 61/M PO Bu, 5 mg/kg ATG CYA
21 MDS/RAEBT 32/M 3 Previous allo 35/M IV Bu, 15 mg/kg ATG CYA/MTX
22 NHL follicular 51/F 5 Previous auto 42/F IV Bu, 15 mg/kg ATG CYA/MTX
23 MM 44/M 2 Previous auto 39/M IV Bu, 15 mg/kg ATG CYA/MTX
24 CLL 59/M 4 Age 61/F IV Bu, 15 mg/kg ATG CYA/MTX
25 NHL DLC 42/F 3 Previous auto 54/F IV Bu, 15 mg/kg ATG CYA/MTX
26 CML AP 47/F 2 Previous allo 51/F IV Bu, 15 mg/kg ATG CYA/MTX
27 MM/plasmacytoma 42/M 2 Previous auto 40/F IV Bu, 15 mg/kg ATG CYA/MTX
28 MDS/RA 59/M 2 Age 57/M IV Bu, 15 mg/kg ATG CYA/MTX
29 NHL MC 62/M 2 Previous auto 65/F IV Bu, 15 mg/kg ATG CYA/MTX
30 CLL 54/M 4 CAD 61/F IV Bu, 15 mg/kg ATG CYA/MTX
*CML indicates chronic myelogenous leukemia; CP, chronic phase; IV Bu, intravenous busulfan, ATG, antithymocyte globulin; CYA, cyclo-
sporine; coag, coagulopathy; PXE, psuedoxanthoma elasticum; PO Bu, oral busulfan; MDS, myelodysplastic syndrome; CMML, chronic
myelomonocytic leukemia; NHL, non-Hodgkin’s lymphoma; MC, mantle cell; AML M-7, acute myelogenous leukemia FAB type M-7; allo, allogeneic
stem cell transplantation; MM, multiple myeloma; auto, autologous stem cell transplantation; MTX, methotrexate; CLL, chronic lymphocytic
leukemia; BP, blast phase; MI, myocardial infarction; RA, refractory anemia; DLC, diffuse large cell; HD, Hodgkin’s disease; MF, myeloﬁbrosis;
RAEBT, refractory anemia with excess blasts in transformation; AP, accelerated phase; age, age greater than 55 years.
†All patients received the same dose of ﬂudarabine.
P. J. Shaughnessy et al.
424
2 and 21 months posttransplantation. Four of the 5 had
responding disease but were being treated with systemic cor-
ticosteroids for acute or chronic GVHD. Another patient
died of sepsis during corticosteroid treatment for refractory
multiple myeloma posttransplantation. Fungal infections
were diagnosed in 3 patients who were receiving corticos-
teroids for treatment of GVHD. In 1 patient Mucor sp was
identified on a single surveillance blood culture with no
identiﬁable source and no subsequent positive cultures. The
2 other patients died of disseminated Aspergillus sp infection.
Nine patients developed CMV reactivation. Eight of the
9 patients were on systemic corticosteroids for GVHD. The
1 patient not receiving corticosteroids developed a CMV
infection that occurred prior to neutrophil engraftment and
involved the lungs, gastrointestinal tract, and bladder.
Survival
Disease response and survival data are summarized in
Table 2. Actuarial OS and DFS at 12 months were 52% (95%
conﬁdence interval [CI], 43%-63%) and 30% (95% CI, 24%-
37%), respectively (Figure 1). As of this report, 14 patients had
died. Causes of death included progressive disease (n = 6),
infection (n = 5), GVHD (n = 1), gastrointestinal hemorrhage
(n = 1), and cerebral vascular accident (n = 1). Actuarial esti-
mates of TRM at 3 months were 7% (95% CI, 6%-8%) and at
12 months were 28% (95% CI, 23%-34%) (Figure 2). Five of
the 6 patients who died of disease progression did not develop
GVHD. One patient, who developed grade II acute GVHD,
had disease progression after initiation of treatment with sys-
temic corticosteroids. There were 16 surviving patients, 8 in
complete response (CR), 1 in partial response (PR), and 7 with
relapsed or persistent disease. All patients alive with CR or PR
developed acute or chronic GVHD. Two surviving patients
with relapsed disease also developed chronic GVHD.
Two patients who had a previous ASCT were alive as of
this report, but both had persistent disease and had lost donor
chimerism. Three of the 4 patients who had undergone previ-
ous autologous stem cell transplantation and obtained a CR
had non-Hodgkin’s lymphoma, and 1 patient with multiple
myeloma had a PR. Two other patients with multiple
myeloma who had undergone previous autologous stem cell
transplantation initially responded, but their disease later pro-
gressed despite the development of extensive chronic GVHD.
DISCUSSION
Slavin and colleagues reported the use of a busulfan, ﬂu-
darabine, and antithymocyte-containing regimen to treat
Table 2. Engraftment, Response, and Survival Characteristics*
Patient % Donor Chimerism Acute Chronic Disease
ID Day 28 Day 56 Day 80 DLI GVHD GVHD Response Survival (mo)/COD/DS 
1 5 50 0 Yes ×1 None No PD Alive (26)/PD 
2 >95 99 100 No Grade II No CR Alive (25)/CR
3 95 90 0 Yes ×2 None No CR Died (9)/DOD/relapsed 3 mo 
4 >95 90-95 >98 No Grade II Yes CR Died (21)/Aspergillus/CR
5 Not done >98 98 No Grade II No CR Died (12)/CVA/relapsed 11 mo 
6† Not done >98 Died No Grade IV NA CR Died (3)/GVHD/CR
7 90 90 Died No Grade II NA PD Died (3)/sepsis/PD
8 65 100 100 No Grade IV Yes CR Died (5)/sepsis/CR
9 100 95 >95 No Grade I No PD Died (4)/GI bleed/PD
10 100 100 100 No Grade II No CR Died (4)/Aspergillus/CR
11 100 >95 >95 No Grade II Yes PR Alive (17)/relapsed 6 mo
12 100 Not done Died No None NA PD Died (2)/DOD
13 >98 100 100 No Grade I Yes PR Alive (15)/relapsed 11 mo 
14 100 90 100 No None NA PR Died (3)/sepsis/relapsed 3 mo
15 Not done 100 100 No None Yes CR Alive (14)/CR
16 88 50 3 Yes ×3 None No PD Alive (14)/PD
17 91 83 Not done No None No PD Died (5)/DOD
18 95 77 40-50 Yes ×2 None No PD Alive (12)/PD
19 95 100 Died Yes ×1 None NA PD Died (2)/DOD
20 100 100 100 No Grade II Yes CR Alive (13)/CR
21 Not done Not done Not done No Grade II NA PD Died (2) DOD
22 100 100 100 No Grade II Yes CR Alive (9)/CR 
23 90 100 100 No Grade II No PR Alive (9)/PR
24 100 100 100 No Grade II Yes CR Alive (7)/CR
25 100 100 100 No Grade III Yes CR Alive (7)/CR
26 40 10 Not done Yes ×2 None No PD Alive (7)/PD
27 100 100 100 Yes ×1 None No PD Died (3)/DOD
28 Not done Not done 100 No Grade II No PD Alive (5)/PD
29 100 100 Not done No Grade III No CR Alive (5)/CR
30 93 100 100 No Grade II No CR Alive (4)/CR
*DLI indicates donor lymphocyte infusion in ﬁrst 100 days; COD, cause of death; DS, disease status; PD, persistent disease; DOD, dead of dis-
ease; NA, not applicable; CVA, cerebral vascular accident; GI bleed, gastrointestinal hemorrhage.
†Patient given IL-2 off study after engraftment.
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standard-risk ASCT patients [25]. In their initial experience
with this regimen it appeared to be sufﬁciently immunosup-
pressive and cytotoxic to allow for adequate engraftment
and control of disease, yet have greater potential to reduce
RRT than standard preparative regimens. In our current
study we expanded the use of a similar regimen to treat
patients at high risk for RRT in a multi-institutional setting.
The incidence of RRT was minimal for this regimen.
Several reports have indicated high mortality rates because of
RRT in patients that have received previous high-dose ther-
apy [7,8]. Other reports have found that patients with multi-
ple myeloma treated with ASCT have excessive TRM as well
[21]. We observed no toxic deaths within the ﬁrst 30 days of
the transplantation and overall acceptable RRT in this high-
risk group of patients. The low incidence of nonhematologic
RRT that we observed was comparable to that reported by
others using a similar regimen [30]. TRMs at 3 and 12 months
were 7% and 28%, respectively, and were most often due to
infection. Infectious complications were a major source of
morbidity and the leading cause of nonrelapse mortality in
this study. The less intensive cytotoxic properties of this con-
ditioning regimen resulted in fewer serious early infections,
but its profound and prolonged immunosuppressive proper-
ties appeared to have predisposed patients to later infectious
complications. The addition of systemic corticosteroids to
control acute and chronic GVHD appeared to contribute to
the infectious mortality in these high-risk patients who were
already severely immunosuppressed.
We observed no clinical evidence of VOD in any
patient, in contrast to the 15% incidence of severe or mod-
erate VOD observed by Slavin et al. [25]. The absence of
VOD in this study may be related to different grading crite-
ria or the incorporation of intravenous versus oral busulfan
in our protocol. Pulmonary toxicity was observed in
1 patient with the occurrence of diffuse interstitial inﬁltrates
and ventilator dependence beginning 3 days posttransplan-
tation. An open lung biopsy later conﬁrmed the diagnosis of
BOOP. This patient had received a prior allogeneic trans-
plant and, upon relapse with CML blast crisis, was treated
with induction chemotherapy prior to treatment on proto-
col. Pulmonary toxicity was also seen in another patient who
received IL-2 off protocol after engraftment. This patient
Figure 1. Patient survival.
Figure 2. Transplantation-related mortality.
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was included in the overall assessment of outcomes because
the preparative regimen was given on study. At the comple-
tion of the IL-2 infusion the patient developed capillary leak
syndrome and hypotension requiring mechanical ventilation
and vasopressor support. The patient subsequently recov-
ered but developed grade IV acute GVHD.
Serum sickness has not been described as a significant
problem in other reports. We found that 37% of patients
exhibited some form of this syndrome and it was the only
reason for a hospital admission in 4 patients. Serum sickness
was differentiated from GVHD by the constellation of
symptoms involving fever, arthralgias, and myalgias with an
erythematous rash that was more serpiginous than macular/
papular. Skin biopsies were done to conﬁrm histologic evi-
dence of GVHD if a rash was the predominant finding.
Patients with isolated myalgias or arthralgias were given nar-
cotics for pain relief, and isolated rashes were treated with
topical steroids or observation (after skin biopsy). Patients
with more severe symptoms or combinations of symptoms
were treated with a pulse of 1 mg/kg of corticosteroids for
1 to 5 days. It is possible that this constellation of signs and
symptoms could still represent engraftment syndrome or
early acute GVHD. Skin biopsies may not be diagnostic of
GVHD at this early point posttransplantation; the clinical
characteristics can overlap and improvement on systemic
corticosteroid treatment can be seen for each diagnosis.
Six patients (20%) required no blood product transfusion
support, but the median number of days to neutrophil and
platelet recovery was similar to that reported for transplanta-
tion employing standard preparative regimens. Febrile neu-
tropenia occurred in more than half of the patients in this
study, necessitating hospitalization and the administration of
intravenous broad-spectrum antibiotics. This outcome was
disappointing, as we initially intended for this regimen to be
administered and managed in the outpatient setting. Ulti-
mately, 29 of the 30 patients were hospitalized at some point
during the ﬁrst 30 days for febrile neutropenia, administra-
tion of intravenous busulfan, and/or ATG toxicity.
Minimal GVHD prophylaxis and a rapid taper of
immunosuppression after engraftment were employed to
expedite the development of a GVM response. Severe GVHD
and the use of systemic corticosteroids to control GVHD
appeared to contribute to excess morbidity and mortality in
the ﬁrst cohort of patients. MTX was added to the CYA for
prophylaxis, and subsequently no patients had grade IV acute
GVHD. The dose of ATG was also increased in 15 of the
17 patients who received CYA/MTX, possibly affecting the
incidence of GVHD. Four of the 6 patients who died of pro-
gressive disease were in the group of patients who received
CYA/MTX and the higher dose of ATG, and these 4 patients
did not develop GVHD. This observation suggests that the
improvement in immunosuppression may have contributed
to a decreased GVM effect. Three patients had full donor
chimerism and acute or chronic GVHD at the time of dis-
ease progression, demonstrating that some malignant clones
are immunoresistant and progress too rapidly for, or are not
responsive to, the GVM effect.
Six of 7 patients who were alive in complete remission
had lymphoid malignancies. This study was not designed to
detect differences between disease entities, and it is unclear
whether this observation is due to bias because of the small
number of patients studied, or there is an intrinsic advan-
tage of the GVM effect with lymphoid malignancies. It is
possible that the busulfan and fludarabine in this regimen
allowed for more effective cytotoxic debulking of lymphoid
diseases and, therefore, more time to develop a meaningful
GVM effect. Other studies in patients with lymphoid
malignancies have reported similar favorable responses
using different preparative regimens [27], suggesting that
the composition of the preparative regimen may be less
important than the development of GVM.
Our disappointing results in patients with myeloid
malignancies may have several explanations in addition to
the small sample size and selection bias. Patients with
myeloid malignancies in our study tended to have under-
gone very heavy pretreatment, and this group of patients
included all of the 6 patients who had undergone a previous
ASCT. It is possible that the ﬂudarabine, busulfan, and ATG
regimen was not the optimal regimen for these patients. For
example, Giralt et al. at MD Anderson Cancer Center have
reported a 64% CR rate in patients with acute myelogenous
leukemia, CML, and myelodysplastic syndrome using
preparative regimens containing melphalan and purine
analogs [40]. In our patients with CML, 2 patients had dis-
ease that had progressed beyond chronic phase at the time
of transplantation, and both had undergone a previous
ASCT. Of the 4 patients with CML chronic phase, 1 had
undergone a previous allogeneic transplantation using a
donor who was mismatched at 1 HLA antigen, and the
other 3 patients were greater than 1 year from diagnosis and
had other comorbidities.
Patients who had previously undergone a conventional
ASCT did poorly in this study, irrespective of other factors.
RRT was acceptable in these patients, but disease control was
not achieved. Three of the 6 patients who had less than 90%
donor chimerism at day 80 had undergone a previous ASCT.
Five of the 6 patients used the same donor, and 1 patient,
whose donor was mismatched for 1 antigen at the A locus,
used another sibling. It is possible that minor histocompati-
bility antigen sensitization may have contributed to the lack
of donor engraftment and eventual disease progression in
these patients.
Actuarial overall survival (52%) and disease free survival
(30%) at 12 months were much less for patients in this study
than for those reported by Slavin et al. [25]. We believe this
result to be due to signiﬁcant differences in the patient popu-
lation under study. Unlike the heavily pretreated patients in
our study, patients in the previous report had not undergone
previous ASCT, and many would have been eligible for con-
ventional preparative regimens. Moreover, our patients were
older and had more comorbidities. However, our protocol
and that used by Slavin et al. had differences that preclude
direct comparisons. The equine ATG used in our study and
the rabbit ATG (Fresenius AG, Munich, Germany) used in
the previous report may have different immunosuppressive
properties that would have affected engraftment and GVHD
rates. Substituting IV busulfan for oral busulfan may have
also changed the toxicity proﬁle, and both changes could have
affected survival outcomes. Our data compare more favorably
with other reports of using reduced-intensity preparative reg-
imens in similar patient populations [26-40]; however, com-
parisons are difﬁcult because of the heterogeneity of patients,
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diseases, and preparative regimens. In the largest series
reported to date of high-risk patients (n = 86) treated with
reduced-intensity preparative regimens, the OS and DFS at
2 years were 28% and 23%, respectively [40]. The Seattle
group has reported an OS of 67% at a median follow-up
period of 417 days in 45 patients with relative contraindica-
tions to conventional ASCT who were treated with low-dose
total body irradiation; however, this study primarily included
patients with more indolent hematologic diseases and acute
leukemia in CR [41].
In conclusion, a reduced-intensity preparative regimen
consisting of ﬂudarabine, busulfan, and ATG can be safely
administered in a multicenter trial to high-risk, heavily pre-
treated patients, including those who have received prior
high-dose chemotherapy, with minimal RRT and acceptable
engraftment. Disease response and long-term control
occurred only in patients who developed GVHD, suggest-
ing that GVHD and GVM are tightly linked. Control of
GVHD with additional immunosuppression led to serious
morbidity and several deaths from infection in this study.
The same risk factors that preclude patients from ASCT
because of RRT may also preclude patients because of
excessive GVHD and infectious risks. Further study is
needed to prevent and treat GVHD and infectious compli-
cations in these high-risk patients. Ultimately, the most
effective way to reduce toxicity of ASCT is to continue efforts
to separate the GVH and GVM effects. In the future, larger
collaborative efforts will be needed to perform randomized,
prospective, disease-specific studies with reduced-intensity
preparative regimens to optimize patient populations that
are best served by this treatment.
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